Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Wetter, Axel ^a   Nensa, Felix ^a   Schenck, Marcus ^a   Heusch, Philipp ^b   Pöppel, Thorsten ^a   Bockisch, Andreas ^a   Forsting, Michael ^a   Schlosser, Thomas W ^a   Lauenstein, Thomas C ^a   Nagarajah, James ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; CHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; DRUG UPTAKE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CARCINOMA; REFERENCE VALUE; TISSUE DISTRIBUTION; TUMOR BIOPSY; VERY ELDERLY; BIOPSY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RADIOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; CHOLINE; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84904498010     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101571     Document Type: Article

References (33)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907. Review.
2. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, et al. (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166: 2185-2188. (Pubitemid 33065253)
3. Murphy G, Haider M, Ghai S, Sreeharsha B (2013) The expanding role of MRI in prostate cancer. Am J Roentgenol 201: 1229-1238.
4. Wu LM, Xu JR, Gu HY, Hua J, Chen J, et al. (2012) Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. Acad Radiol 19: 1215-1224. Review.
5. Giannarini G, Petralia G, Thoeny HC (2012) Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61: 326-340.
6. Kitajima K, Takahashi S, Ueno Y, Miyake H, Fujisawa M, et al. (2013) Do apparent diffusion coefficient (ADC) values obtained using high b-values with a 3-T MRI correlate better than a transrectal ultrasound (TRUS)-guided biopsy with true Gleason scores obtained from radical prostatectomy specimens for patients with prostate cancer? Eur J Radiol 82: 1219-1226.
7. Bonekamp S, Corona-Villalobos CP, Kamel IR (2012) Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 35: 257-279. Review.
8. Bains LJ, Zweifel M, Thoeny HC (2012) Therapy response with diffusion MRI: an update. Cancer Imaging 28: 395-402.
9. Thoeny HC, Ross BD (2010) Prediciting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32: 2-16.
10. Baumann G, Belhocine T, Kovacs M, Ward A, Beheshti M, et al. (2012) 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 15: 45-55.
11. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, et al. (2010) 18 F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254: 925-933.
12. Challapalli A, Barwick T, Tomasi G, O'Doherty M, Contractor K, et al. (2014) Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl Med Commun. 35: 20-29.
13. Wetter A, Lipponer C, Nensa F, Beiderwellen K, Olbricht T, et al. (2013) Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol. 48: 256-262.
14. Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd'hotel C, et al. (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 50: 520-526.
15. Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, et al. (2014) Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging 41: 79-88.
16. Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, et al. (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40: 1486-1499.
17. Rakheja R, Chandarana H, DeMello L, Jackson K, Geppert C, et al. (2013) Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. Am J Roentgenol 201: 1115-1119.
18. Nakajo M, Nakajo M, Kajiya Y, Tani A, Kamiyama T, et al. (2012) FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Clin Nucl Med 37: 475-480.
19. Varoquaux A, Rager O, Lovblad KO, Masterson K, Dulquerov P, et al. (2013) Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging 40: 842-852.
20. Choi SH, Paeng JC, Sohn CH, Pagsisihan JR, Kim YJ, et al. (2011) Correlation of 18F-FDG uptake with apparent diffusion coefficient ratio measured on standard and high b-value diffusion MRI in head and neck cancer. J Nucl Med 52: 1056-62.
21. Glunde K, Bhujwalla ZM, Ronen SM (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848. Review.
22. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, et al. (2002) Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296: 580-583.
23. Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, et al. (2011) Use of [11C] choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 17: 7673-7683.
24. Zhang J, Jing H, Han X, Huang Z, Cao Z, et al. (2013) Diffusion-weighted imaging of prostate cancer on 3T MR: Relationship between apparent diffusion coefficient values and Ki-67 expression. Acad Radiol 20: 1535-1541.
25. Bae H, Yoshida S, Matsuoka Y, Nakajima H, Ito E, et al. (2013) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 2014 46: 555-561.
26. Heijmen L, Ter Voert EE, Nagtegaal ID, Span P, Bussink J, et al. (2013) Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 23: 748-756.
27. Borren A, Moman MR, Groenendaal G, Boeken Kruger AE, van Diest PJ, et al. (2013) Why prostate tumour delineation based on apparent diffusion coefficient is challenging: an exploration of the tissue microanatomy. Acta Oncol 52: 1629-1636.
28. Nagel KN, Schouten MG, Hambrock T, Litjens GJ, Hoeks CM, et al. (2013) Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 267: 164-172.
29. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, et al. (2007) Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34: 45-53. (Pubitemid 44885553)
30. 11C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model. Nuklearmedizin 52: 141-147.
31. De Waele A, Van Binnebeek S, Mottaghy FM (2010) Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT. Clin Nucl Med 35: 701-703.
32. Song I, Kim CK, Park BK, Park W (2010) Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. Am J Roentgenol. 194: W477-482. Erratum in: Am J Roentgenol 195: 534.
33. Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR (2011) Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol 6: 65. doi:10.1186/1748-717X-6-65.